Ivermectin (3 mg tablet)

MSF strongly supports the inclusion of ivermectin as an intestinal anthelminthic in both the WHO Model List of Essential Medicines and the WHO Model List of Essential Medicines for Children (section 6.1.1).

MSF supports the application of the WHO Department of Control of Neglected Tropical Diseases for the extension of the indication of ivermectin which is currently included in the WHO Model List of Essential Medicines as an antifilarial (section 6.1.2).

MSF agrees to include ivermectin alone for use against Strongyloides stercoralis infection and to include ivermectin co-administered with albendazole for use against soil-transmitted helminthiasis (i.e. Ascaris lumbricoides (roundworm), Trichuris trichiura (whipworm), and Ancylostoma duodenale and Necator americanus (hookworms)).

For strongyloidiasis, ivermectin is administered in a single-dose of 200 µg ivermectin/kg for both adults and children over the age of 5 or with a minimum body weight of 15 kg.

For soil-transmitted helminthiasis, ivermectin is administered in a single-dose of 200 µg ivermectin/kg with a single-dose tablet of 400 mg albendazole for both adults and children over the age of 5 or with a minimum body weight of 15 kg.

MSF has been using ivermectin in its programs since 2001.

MSF urges the 21th Expert Committee on the Selection and Use of Essential Medicines to include ivermectin as an intestinal anthelminthic in both the WHO Model List of Essential Medicines and the WHO Model List of Essential Medicines for Children.

For Médecins Sans Frontières

Myriam Henkens, MD, MPH
International Medical Coordinator